Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTXNYSE:LCINASDAQ:NEPTNASDAQ:STSANASDAQ:SVRA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTXAptinyx$0.10+3.1%$0.08$0.01▼$0.72N/A1.271.32 million shs231,100 shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsNEPTNeptune Wellness Solutions$0.43$0.19▼$28.00$906K2.19462,687 shs2.25 million shsSTSASatsuma Pharmaceuticals$1.10-0.9%$1.08$0.59▼$8.08$36.47M0.1701,788 shs1.83 million shsSVRASavara$4.85-1.2%$4.93$1.63▼$5.70$670.03M0.77823,521 shs356,279 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTXAptinyx0.00%0.00%0.00%+3.17%-27.27%LCILannett0.00%0.00%0.00%0.00%-56.06%NEPTNeptune Wellness Solutions0.00%0.00%-45.95%-64.05%-98.95%STSASatsuma Pharmaceuticals0.00%0.00%0.00%0.00%+30.95%SVRASavara-1.22%-0.82%-7.09%+0.62%+137.75%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTXAptinyxN/AN/AN/AN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/AN/AN/AN/ANEPTNeptune Wellness Solutions0.5053 of 5 stars0.03.00.00.03.20.80.6STSASatsuma Pharmaceuticals2.8388 of 5 stars3.00.00.04.40.03.30.6SVRASavara2.2544 of 5 stars3.51.00.00.03.12.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTXAptinyxN/AN/AN/AN/ALCILannettN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/ASTSASatsuma Pharmaceuticals2.00Hold$2.50127.27% UpsideSVRASavara3.00Buy$8.2069.07% UpsideCurrent Analyst RatingsLatest LCI, SVRA, APTX, STSA, and NEPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/4/2024SVRASavaraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$7.00 ➝ $16.002/15/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTXAptinyx$1MN/AN/AN/A$0.57 per shareN/ALCILannett$340.58M0.00N/AN/A($23.34) per share0.00NEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00STSASatsuma PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/ASVRASavaraN/AN/AN/AN/A$1.04 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/A3/28/2024 (Estimated)LCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/ANEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)STSASatsuma Pharmaceuticals-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/ASVRASavara-$54.70M-$0.33N/AN/AN/AN/A-46.27%-35.94%5/20/2024 (Estimated)Latest LCI, SVRA, APTX, STSA, and NEPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023SVRASavara-$0.11-$0.09+$0.02-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTXAptinyxN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTXAptinyxN/AN/AN/ALCILannettN/A2.231.39NEPTNeptune Wellness SolutionsN/A0.230.10STSASatsuma PharmaceuticalsN/A7.447.44SVRASavara0.1915.6615.66OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTXAptinyxN/ALCILannett40.28%NEPTNeptune Wellness Solutions14.44%STSASatsuma Pharmaceuticals93.26%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipAPTXAptinyx10.97%LCILannett13.12%NEPTNeptune Wellness Solutions5.10%STSASatsuma Pharmaceuticals31.20%SVRASavara4.58%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTXAptinyx12N/AN/ANot OptionableLCILannett81010.77 million9.35 millionOptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableSTSASatsuma Pharmaceuticals2133.15 million22.81 millionNot OptionableSVRASavaraN/A138.15 million131.82 millionOptionableLCI, SVRA, APTX, STSA, and NEPT HeadlinesSourceHeadlineDetails of Savara’s Upcoming Projectsghettoradio.co.ke - March 27 at 5:19 AMSavara Announces New Employment Inducement Grantbusinesswire.com - March 22 at 4:05 PMSavara: Why Sauti Sol had to take a break from each othermpasho.co.ke - March 19 at 4:25 AMSavara Inc. Reports Increased Expenses, Anticipates Positive Data from IMPALA-2 Trialmsn.com - March 13 at 1:33 PMPolar Capital Holdings Plc Makes New Investment in Savara Inc (NASDAQ:SVRA)marketbeat.com - March 13 at 7:54 AMFDA lifts partial hold on Nurix Phase 1 study for NX-2127msn.com - March 11 at 6:57 PMBuy Rating Affirmed: Anticipating IMPALA-2 Trial Success and aPAP Treatment Breakthrough with Molgramostimmarkets.businessinsider.com - March 11 at 1:57 PMSavara (NASDAQ:SVRA) Shares Down 5.5% marketbeat.com - March 11 at 1:22 PMSVRA Jul 2024 7.500 callfinance.yahoo.com - March 10 at 9:20 AMOptimistic Buy Rating for Savara on Molgramostim’s Market Potential and Strong Financialsmarkets.businessinsider.com - March 8 at 9:43 AMSVRA Stock Earnings: Savara Beats EPS for Q4 2023msn.com - March 7 at 11:08 PMSavara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Updatefinance.yahoo.com - March 7 at 6:08 PMBest penny stocks of March 2024usatoday.com - March 6 at 4:44 PMSavara to Present at the Barclays 26th Annual Global Healthcare Conferencefinance.yahoo.com - March 6 at 4:44 PMAdage Capital Partners GP L.L.C. Acquires 1,874,000 Shares of Savara Inc (NASDAQ:SVRA)marketbeat.com - March 6 at 8:19 AMSavara (NASDAQ:SVRA) Reaches New 1-Year High on Analyst Upgrademarketbeat.com - March 4 at 10:30 AMSavara (NASDAQ:SVRA) Given New $16.00 Price Target at Piper Sandlermarketbeat.com - March 4 at 8:24 AMBensoul, Nviri, Savara, Father Moh, Jovial, Ndovu Kuu, and Mandy team up for new hit song 'Tujengane'mpasho.co.ke - March 2 at 9:23 AMPiper Sandler Keeps Their Buy Rating on Savara (SVRA)markets.businessinsider.com - March 1 at 2:54 PMSavara (SVRA) Price Target Increased by 22.98% to 7.21msn.com - February 24 at 7:32 AMSavara Inc. (YB4P.F)au.finance.yahoo.com - February 22 at 7:52 AMSee Leaked Details of Bensoul, Nviiri and Savara's Music Projectmsn.com - February 21 at 12:05 AMSavara Inc. (NASDAQ:SVRA): Are Analysts Optimistic?finance.yahoo.com - February 20 at 2:05 PMJMP starts Savara at buy, cites market potential for lung disease drugmsn.com - February 15 at 3:52 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAptinyxNASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.LannettNYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. Satsuma PharmaceuticalsNASDAQ:STSASatsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.SavaraNASDAQ:SVRASavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.